Zactima meets thyroid cancer endpoint

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Zactima vandetanib met the primary endpoint of significantly improving progression-free survival (PFS) vs. placebo in the Phase II ZACTHYF trial to treat locally advanced or metastatic papillary or follicular thyroid cancer (11 vs. 5.8 months, p=0.008). The double-blind study enrolled 145 patients who failed treatment with or were unsuitable for treatment with radioiodine therapy. Data were presented at the International Thyroid meeting in Paris. ...